EGFR and non-small cell lung carcinoma: From the perspective of a U.S. payer, osimertinib was unlikely to be cost-effective compared to placebo for patients with stage IB to IIIA, EGFR-mutated, completely resected NSCLC at a WTP threshold of $150,000/QALY.